Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 20,100 shares, an increase of 118.5% from the May 31st total of 9,200 shares. Based on an average daily trading volume, of 18,200 shares, the days-to-cover ratio is presently 1.1 days. Approximately 2.6% of the company’s shares are short sold.

Hedge Funds Weigh In On Vaccinex

An institutional investor recently bought a new position in Vaccinex stock. Armistice Capital LLC bought a new position in shares of Vaccinex, Inc. (NASDAQ:VCNX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 680,000 shares of the company’s stock, valued at approximately $768,000. Armistice Capital LLC owned 15.45% of Vaccinex as of its most recent SEC filing. Institutional investors own 50.11% of the company’s stock.

Vaccinex Stock Up 5.0 %

VCNX traded up $0.31 during trading on Friday, hitting $6.49. The company’s stock had a trading volume of 7,230 shares, compared to its average volume of 40,662. Vaccinex has a twelve month low of $4.43 and a twelve month high of $83.56. The stock’s fifty day moving average price is $6.00 and its 200-day moving average price is $7.50. The firm has a market capitalization of $10.25 million, a P/E ratio of -0.08 and a beta of 0.86.

Vaccinex (NASDAQ:VCNX) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($2.94) earnings per share (EPS) for the quarter. The business had revenue of $0.10 million during the quarter.

About Vaccinex

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.